Novo Nordisk reports 20% increase in H1 sales  

2006.08.03
Danish healthcare company Novo Nordisk, a world leader in diabetes care, increased its H1 sales by 20% to DKK 18.7 bn

Danish healthcare company Novo Nordisk, a world leader in diabetes care, increased its H1 sales by 20% to DKK 18.7 bn (USD 3.2 bn). Operating profit rose by 17% to DKK 4.5 bn (USD 765 m), while net profit stayed largely unchanged at DKK 2.95 bn (USD 500 m). Lars Rebien Sørensen, president and CEO of Novo Nordisk comments:

"Our business has performed very well in the first six months of 2006 in terms of both sales and production economics. This enables us to upgrade expectations for the whole year for both sales and operating profit." Novo Nordisk forecasts sales growth of 13-15%, and growth in operating profit of around 13%.

Following the announcement of the company's strong H1 results, Novo Nordisk shares rose 6% on Copenhagen Stock Exchange on Wednesday, corresponding to an increase in the company's market value of DKK 137 bn (USD 23.3 bn). The news was widely reported by the Danish press.

Novo Nordisk is headquartered in Bagsværd, north of Copenhagen, and employs 22,000 people in 79 countries. The company has the broadest product portfolio in the diabetes industry, including advanced products in the area of insulin delivery systems. It also has a leading position in areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.

Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×